Navigation Links
Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
Date:11/26/2008

at involve a number of risks and uncertainties, including whether the closing conditions, including the consent of Biogen Idec, Inc., will be satisfied in order to consummate the joint venture transaction, the success of the joint venture in commercializing and developing ZEVALIN, the ability of the joint venture to accelerate top-line revenues in the near-term, and the ability to integrate ZEVALIN into Spectrum's commercial, marketing and medical affairs teams ,the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of ZEVALIN include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with ZEVALIN in particular including, without limitation, the potential for ZEVALIN FIT data to be acceptable to the FDA for this expanded indication or any other indication, the potential that the FDA will not grant priority review to the sBLA, the ability of CTI to continue to raise capital to fund its operations, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling ZEVALIN. There is also a risk that even if label expansion of ZEVALIN is approved, it may not result in a significant market increase for the drug due to the presence of other treatment options, failure to gain market acceptance and other factors. You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

     Spectrum Contacts
     Russell Skibsted - Chief Busi
'/>"/>
SOURCE Spectrum Pharmaceuticals, Inc.; Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. GEECF: Spectrum Launches Zero Waste Philippines and Gears Towards Cheap Green Energy
2. Geecf: Spectrum Blue Steel Announces Strategic Partnership with Al Manhal International Group of Abu Dhabi to Deploy Biosphere Facilities
3. "Brave New Reality" Provides a Wide Spectrum of High Tech News and Easy Science.
4. Spectrum Blue Steel's fresh foreign investment at 18 Billion and the Biosphere process spark attention on a global scale
5. Energetiqs Laser-Driven Light Source Technology Enables Continuous Spectrum Light Sources, from Visible to Deep Ultraviolet
6. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
7. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
8. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
9. Global Experts Explore Entire Spectrum of Aids Vaccine Development
10. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... The North American crystal oscillator market ... with analysis and forecast of revenue. This market was ... to reach $623.6 million by 2018, at a CAGR ... the TOC of the North American crystal oscillator market ... provided. This also provides a glimpse of the segmentation ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, announced today ... a Notice of Allowance for a composition of matter ... C. difficile program, SYN-004. This is Synthetic Biologics, ... the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 /PRNewswire/ ... announced today that rare disease expert John C. ... research. Dr. McKew brings more than two decades of ... the National Institutes of Health, Wyeth Research and Genetics ... will lead aTyr,s efforts to expand and translate its ...
Breaking Biology Technology:The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... Fuld & Company today announced that Wayne Rosenkrans, ... specializing in strategic gaming for the pharmaceutical and healthcare ... "We are excited to have Dr. Rosenkrans join ... accomplishment in the global pharmaceutical industry; government and academia ...
... tartrate sublingual lozenge) as the first sleep aid specifically ... , PT. RICHMOND, Calif., Dec. ... company, announced today that it has received confirmation from ... New Drug Application (NDA) for Intermezzo (R) (zolpidem ...
... Sciences, Inc., a,privately-held, development-stage pharmaceutical company dedicated to ... mucosal defenses, today,announced that the National Institutes of ... in excess of $850,000. , ... is to advance the development of safe and,effective ...
Cached Biology Technology:Fuld & Company Announces Appointment of MIT Fellow to Head Pharmaceutical Team's Strategic Gaming and Consulting Services 2Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 2Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 3Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 4Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 5Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury 2Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury 3
(Date:10/16/2014)... of Marine Science have received a 3-year, $392,773 ... the streams and wetlands most vulnerable to sea-level ... governments and citizens conserve these important ecosystems. , ... tidal-marsh observations first gathered by VIMS scientists in ... today,s researchers accurately map the slow but inexorable ...
(Date:10/16/2014)... be cultivated efficiently, they are anything but sustainable: ... monoculture cultivation is becoming increasingly evident. Despite their ... and are regarded as the sole possibility of ... wrongfully, finds Bernhard Schmid, an ecology professor at ... form of agriculture and forestry. After all, a ...
(Date:10/16/2014)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market announces ... the Smart Wallet, at the 13 th annual ... global conference on the intersection of technology and the ... , founder and publisher of the Strategic News Service™, ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... University researchers have found a potential clue to the ... While studying the peripheral nerves of the Drosophila, ... discovered an unanticipated connection between glutamate an amino ... eat and phosphoinositide 3-kinase (PI3K), an enzyme that, ...
... decreasing the growth of trees in the northern and temperate ... Global Change Biology . Tree growth, measured in biomass, ... is set to increase to a 17% reduction by the ... greater now than prior to the Industrial Revolution in the ...
... from Penn State University and the University of Chicago has ... virus, called N4, injects an unusual substance -- an RNA ... cell. The results, which are published in the current ... improved understanding of the infection strategies used by viruses that ...
Cached Biology News:Rice University study finds possible clues to epilepsy, autism 2Rice University study finds possible clues to epilepsy, autism 3Surface-level ozone pollution set to reduce tree growth 10 percent by 2100 2Properties of unusual virus revealed in research 2Properties of unusual virus revealed in research 3
GFX PCR DNA,Gel Band Purif,100, 1 EA. Category: Nucleotide Sample Handling....
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed...
... Standard Tray (3 per pack), 1. ... and blot processing.Automated staining of Coomassie ... and nucleic acid analysis.Prepares blots for ... detection.Programmable control of protocol, solution, volume, ...
GOAT ANTI HUMAN PARAINFLUENZA VIRUS 2+3...
Biology Products: